2004•Hospital MedicineRequires access

Treatment of intermittent claudication: cilostazol

Patrick Duncan Collins, Julie Brittenden

Open publisher page 1 citations

Abstract

Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease. Treatment involves secondary prevention and measures to improve walking. Cilostazol significantly increases walking distance and quality of life in claudicants.

About this research paper

What this paper is about

Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease. Treatment involves secondary prevention and measures to improve walking. Cilostazol significantly increases walking distance and quality of life in claudicants.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease. Treatment involves secondary prevention and measures to improve walking. Cilostazol significantly increases walking distance and quality of life in claudicants.

Key concepts: Cilostazol, Intermittent claudication, Medicine, Claudication, Quality of life (healthcare), Physical therapy, Disease, Arterial disease

Related papers

Back to paper searchBrowse research topicsOriginal source
Treatment of intermittent claudication: cilostazol — Research Paper | ScholarLens